ing patients with autoimmune diseases, treated in the ICU, who developed DAH, are very limited [7, 8] .
Diagnosis of DAH is complex and poses a par ticular challenge in critically ill patients. The typical clinical symptom -hemoptysis -is present only in approximately one third of cases [1, 4] . The most cru cial imaging method is chest computed tomography (CT), which most often reveals ground glass opacities and/or alveolar consolidation with air bronchogram. Another important diagnostic method is a fibreop tic bronchoscopy with bronchoalveolar lavage (BAL) showing increasing haemorrhage in serial lavages and hemosiderinladen macrophages found in the cytological examination. Basic laboratory tests usu ally show anaemia and, less specifically, increased lactate dehydrogenase (LDH) levels. One of the most typical features of DAH is increased diffusion lung capacity for carbon monoxide (DLCO) in lung func tion tests. The gold standard for the diagnosis of DAH is, however, surgical biopsy [4] . Obviously, in the ICU setting, some of the aforementioned methods pose too high a threat to patients. Therefore the diagnosis needs to be made on the basis of clinical examina tion, imaging and laboratory tests and bronchoscopy.
Our group has recently reported on the high mortality rate of ICU patients with systemic autoim mune diseases reaching up to 70% in 5year follow up [9] . Considering that DAH is one of the most severe autoimmune disease manifestations, due to its sudden onset and potentially fatal outcome, prompt diagnosis and treatment are crucial [10] . Re ported mortality of DAH in the available literature is high but variable, ranging from 20% to 80% [11] . Previous reports suggest that shock, impaired renal function, as well as plasmatic lactate dehydroge nase levels are factors associated with inhospital mortality in this population [12] .
The aim of this study is to describe patients with DAH in the course of systemic autoimmune disease treated in the ICU with survival analysis in a 5year followup.
METHODS
This is an observational, retrospective cohort study, conducted in the ICU of the Allergy and Im munology Department at the University Hospital in Krakow, Poland. The study is a part of the ICU pa tient database project, which was approved by the Jagiellonian University Bioethics Committee. Due to the nature of the study there was no requirement for written informed consent.
The study personnel searched the hospital's electronic database from years 2001-2014 in order to identify patients with the diagnosis of systemic autoimmune diseases treated in the ICU. The 10 th re vision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) codes as well as the full names of the systemic auto immune diseases were used in database screening. Each medical record was later thoroughly assessed to confirm patients' eligibility for the study. Among patients included in the study, those diagnosed with DAH were selected for the analysis. The study flowchart is provided in Figure 1 .
If the patient was treated in the ICU more than once, only the first admission was analyzed. Patients admitted to the ICU only for a single procedure (e.g. dialysis catheter implantation or therapeutic plasma exchange) were excluded from the study. Diagnosis of DAH was made by experienced clini cians according to commonly used criteria including clinical examination, laboratory tests, CT as well as bronchoscopy.
The study personnel gathered demographic, clinical and laboratory data. The reason for the ICU admission, history of autoimmune diseases and im munosuppressive treatment, procedures performed in the ICU and all variables concerning ICU stay were also extracted.
Based on available data from the first 24 hours of ICU stay, the authors calculated the following in dices: Acute Physiology and Chronic Health Evalua tion (APACHE) II and III, Simplified Acute Physiology Score (SAPS) II as well as the Sequential Organ Fail ure Assessment (SOFA) [13] . Patients' survival was assessed at the ICU discharge, 1 year and 5 years after the first ICU admission by phone call follow up and other available resources (Outpatient Clinic Database, National Health Insurance Database).
Records assessment FIGURE 1. The study flowchart ICU's electronic database searched for terms: "systemic lupus erythematosus", "vasculitis", "granulomatosis with polyangiitis", "Wegener's granulomatosis", "eosinophilic granulomatosis with polyangiitis", "Churg-Strauss syndrome", "rheumatoid arthritis", "polymyositis", "dermatomyositis", "scleroderma", "systemic sclerosis", "antiphospholipid syndrome", "connective tissue disease"
Patients with diagnosis of systemic autoimmune disease, treated in the Intensive Care Unit n = 83 9 patients excluded: -6 patients were previously hospitalized in the ICU due to autoimmune disease -3 patients were admitted to ICU for a single procedure n = 74 53 patients excluded due to lack of DAH diagnosis during ICU hospitalization n = 21 ICU's electronic database searched for ICD-10 codes: M05, M06, M30, M31, M32, M33, M34, M35, M36, D68.9, D69
Variables are described as mean with standard deviation (SD) or median with interquartile ranges depending on the data distribution. Comparisons between groups were performed using the c 2 test for categorical variables, whereas continuous vari ables were compared using Student's t test and the Mann Whitney Utest, depending on data distri bution. Survival was defined as the time from the ICU admission to death from any cause and event time distribution was graphically presented using KaplanMeier curves. Differences in mortality be tween the two study groups were assessed using the logrank test. Statistical analysis was performed with StatSoft Statistica 13 software (StatSoft, Tulsa, OK, USA) and RStudio version 1.1.383 (RStudio, Bos ton, MA, USA); packages: survival, survminer. Graphs were prepared with GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) and RStudio version 1.1.383 (RStudio, Boston, MA, USA); packages: sur vival, survminer.
RESULTS

Baseline demographic clinical characteristics
Of 74 patients with systemic autoimmune dis eases treated in the ICU between 2002 and 2014, we selected 21 who developed DAH. The median age of patients was 53 (range: 18-78) years and 13 (61.9%) of them were female. The majority of the patients were diagnosed with granulomatosis with polyan giitis (8/21; 38.1%), systemic lupus erythematosus (5/21; 23.8%) and microscopic polyangiitis (3/21; 14.3%). The autoimmune disease was diagnosed during the ICU hospitalization in 4 cases (19.0%). Diffuse alveolar haemorrhage was the reason for admission in 6 patients (28.6%) and developed dur ing ICU hospitalization in 15 cases (71.4%). The most common comorbidity in this cohort was chronic kidney disease, which was diagnosed in 12 patients (57.1%), 7 (33.3%) of whom had endstage chronic kidney disease. Detailed information concerning basic characteristics of the study group and auto immune disease diagnosis can be found in Table 1 .
Pre-ICU immunosuppressive therapy
The majority of the patients (17/21; 81.0%) were administered at least one immunosuppressive med ication prior to admission to the ICU. Nine patients (42.9%) received longterm steroid therapy, twelve patients (57.1%) cyclophosphamide and in seven patients (33.3%) a combination of these medica tions was used.
ICU hospitalization
The most commonly used causal treatment was steroids in maintenance doses only (14/21, 66.7%), steroid pulses (6/21, 28.6%), cyclophosphamide infusions (6/21, 28.6%) and plasmapheresis (4/21, 19.0%). The majority of the patients required me chanical ventilation (18/21, 85.7%), renal replace ment therapy (12/21, 57.1%) and blood product transfusions (15/21, 71.4%). A detailed description of the ICU management is summarized in Table 2 .
Survival analysis
Almost half of the patients survived the ICU hospitalization (10/21; 47.6%). The survival rate was 23.8% (5/21) in both 1year and 5year followup. Five of the total eleven deaths during ICU stay were related to infection (45.5%). A detailed description [8, 15] as well as recombinant activated factor VII (rFVIIa) [16] . There are also case report series of extracorporeal membrane oxygenation (ECMO) use in severe, hypoxic respiratory failure due to of the survival and the calculated SAPS II, APACHE II, APACHE III and 1st day SOFA scores can be found in Table 3 . The KaplanMeier curve for 1year survival is presented in Figure 2 .
Comparison of study groups
Patients who developed DAH were less often administered steroids before admission to the ICU (42.9% vs. 69.8%, P = 0.03), were more often diag nosed with autoimmune disease in the ICU (19.0% vs. 3.8%, P = 0.03) and achieved a higher SAPS II score (55.0 vs. 41.0, P = 0.014). In terms of treatment dur ing ICU hospitalization, patients with DAH more of ten received steroid pulses (28.6% vs. 9.4%, P = 0.04), cyclophosphamide (28.6% vs. 5.7%, P = 0.007) and renal replacement therapy (57.1% vs. 28.3%, P = 0.02) compared to those who did not develop DAH. We did not observe any significant differences in survival between the groups. Exact data are presented in Tables 4 and 5 . The KaplanMeier curve comparing survival in the two groups is shown in Figure 3 .
DISCUSSION
In this retrospective cohort study, we analysed 21 patients with systemic autoimmune diseases complicated by diffuse alveolar haemorrhage, treat ed in the intensive care unit. It showed that this con dition is associated with high shortterm and long term mortality as well as significant requirement for advanced lifesupport procedures. This is, to our best knowledge, the first study describing characteristics and outcomes of Polish patients with systemic auto immune diseases, treated in the intensive care unit, who developed DAH. It also provides a unique in sight into longterm outcomes of this very specific group of patients.
Our study confirms that among patients with systemic autoimmune diseases, DAH occurs most commonly among patients with ANCAassociated vasculitis. Interestingly, in almost 20% of patients in the study, autoimmune diseases were diagnosed during ICU hospitalization. Similar findings were ob tained in the study by Monti et al., where 30% of ICU diagnosed vasculitis patients had DAH [14] . It high lights the fact that this lifethreatening complication is a hallmark presentation of autoimmune disease in a significant number of patients. In our opinion, these results suggest that there is still room for improve ment in early detection of autoimmune diseases before the most severe presentations, such as DAH, occur and higher vigilance of clinicians is warranted.
Typically, causal treatment of DAH consists of pulse corticosteroids and other intravenous immuno suppressants such as cyclophosphamide [11] . Other reports suggest the use of a monoclonal chimeric an tibody targeting CD20 (rituximab) [4] , plasmapher DAH [17, 18] . In our cohort the majority of patients were treated with steroids, more than 1 in 4 patients required steroid pulses or cyclophosphamide infu sions, in less than 20% of cases plasmaphereses were performed, while none of the patients re ceived rituximab. Due to the lack of welldesigned studies and low prevalence of the described syn drome, there is lack of evidencebased guidelines concerning treatment of DAH in autoimmune dis eases. Hopefully, upcoming publication of PEXIVAS study results [19] will shed more light on the use fulness of plasmapheresis in treatment of DAH, es pecially considering that this topic is controversial, as there is not enough evidence of the treatment benefits, and the plasmapheresis procedure may also be associated with some complications [15] .
It is important to remember that the key to DAH management is the successful treatment of under lying disease [10] . Another interesting observation is high use of advanced therapeutic procedures -the majority of our patients required mechanical ventilation, blood product transfusions and renal replacement thera py. Available literature mentions mainly invasive mechanical ventilation use, which is very variable and ranges from 17% to 70%. However, most of the studies concern patients treated outside the ICU [7, 12, 20] . Such frequent use of renal replacement therapy is probably associated with common renal involvement in autoimmune diseases, while blood product transfusions are related to blood loss result ing from haemorrhage.
Patients enrolled in our study were in a severe clinical condition from the moment of admission, which is reflected in high scores in all prognostic scales. As an example, the median score in SAPS II corresponds with predicted mortality of 57%. Our study showed that more than 50% of patients with systemic autoimmune diseases who developed DAH do not survive ICU hospitalization. In longer followup, there is a significant drop in survival to less than 25% at 1 year. Interestingly, none of the patients died within the following 4 years of obser vation. This finding has emphasized how important for patients' prognosis is the ICU treatment and then checkups during the following year. Compared to previous studies, the mortality in our cohort is mark edly higher. This is probably associated with the fact that our group consists exclusively of patients treat ed in the ICU. When compared to the study by Rabe et al., where DAH was assessed in the ICU setting (but not only in autoimmune diseases), the mortal ity rate is similar [7] .
Additional analysis involving comparison of study groups, suggests that, even among patients with systemic autoimmune diseases, those who de velop DAH are admitted to the ICU in worse clinical condition, receive more intensive immunosuppres sive therapy and more often require renal replace Steroids + other immunosuppressants 7 (33.3%) 28 (52.8%) 0.13 ment therapy. Interestingly, there is no statistically significant difference in terms of survival between the groups. However, this is probably related to the limited sample size as 1year survival in the DAH group is almost two times lower compared to the remaining patients.
Our study has several limitations. First, the study group is small, which limits our ability to perform multivariable analysis to assess e.g. mortality risk factors. Moreover, the retrospective character of the study hinders precise assessment of several crucial features, e.g. cause of death. Also, followup analysis concerned only mortality, and we had no information concerning DAH relapses and rehospi talizations.
CONCLUSIONS
Patients who develop DAH in the course of systemic autoimmune disease and require hospi talization in the ICU are at particularly high risk for mortality, and most of them require mechanical ventilation, renal replacement therapy and blood product transfusions.
